Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
U S Nutraceuticals Inc. D/B/A Valensa International maintains a focused prosecution presence within the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action, which is being handled by 1 examiner. This concentration indicates a specific set of patent applications currently under review by the USPTO. The presence of 1 distinct art unit suggests that the subject matter of the pending work is technically homogeneous.
JENNIFER LYNN CAIN is identified as the busiest examiner for the portfolio, responsible for the 1 busiest examiner pending action. Because there is only 1 distinct examiner across the entire set of pending work, the prosecution strategy currently relies on a centralized point of contact within the patent office. This structure minimizes the complexity of managing multiple examiner styles or art unit requirements simultaneously. The data reflects a focus for the company's current intellectual property efforts in the pharmaceutical sector. Practitioners can observe that the 1 distinct art unit involved simplifies the administrative oversight required for this portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CAIN, JENNIFER LYNN | 1 | 43.5% | +67.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19049072 | DIETARY SUPPLEMENT COMPOSITION HAVING ENHANCED LSESr AND METHOD OF MAKING | CAIN, JENNIFER LYNN | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19049072 | DIETARY SUPPLEMENT COMPOSITION HAVING ENHANCED LSESr AND METHOD OF MAKING | CAIN, JENNIFER LYNN | 1655 | §103§112DP | Non-Final OA | — | Pending | Feb 10, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialU S Nutraceuticals Inc. D/B/A Valensa International has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jennifer Lynn Cain has the most, with 1 of U S Nutraceuticals Inc. D/B/A Valensa International's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
